Last updated: October 28, 2025
Introduction
Acthar Gel (repository corticotropin injection) developed by Mallinckrodt Pharmaceuticals, is a longstanding, FDA-approved therapeutic primarily for multiple sclerosis-related exacerbations, infantile spasms, and certain inflammatory conditions. Its complex patent landscape, evolving clinical data, and expanding off-label uses position it as a unique asset within the neuroimmunology and inflammatory therapeutics market. This report offers an in-depth update on its recent clinical trial landscape, market dynamics, and future projections.
Clinical Trials Landscape for Acthar
Recent Clinical Trial Activity
Over the past three years, Acthar has been the subject of multiple clinical investigations aimed at exploring new indications, optimizing dosing regimens, and confirming safety profiles. The most notable studies include:
-
Multiple Sclerosis (MS): Several phase 4 extension and post-marketing surveillance studies continue evaluating long-term efficacy and safety, particularly for relapsing-remitting MS (RRMS). Recent data suggest a consistent safety profile aligning with previous approvals, but with limited evidence indicating superior efficacy over corticosteroids in acute exacerbations.
-
Infantile Spasms: Ongoing phase 3 trials assess comparative efficacy for Acthar versus adrenocorticotropic hormone (ACTH) and prednisone. Preliminary results show comparable efficacy but with a different side-effect profile, prompting ongoing clinical interest.
-
Autoimmune Conditions: Trials are exploring off-label applications such as idiopathic nephrotic syndrome, systemic lupus erythematosus (SLE), and multiple inflammatory disorders. Most are phase 2 studies, with some showing promising activity, often leading to expanded access programs.
Emerging Indications and Regulatory Developments
Recent years have seen discussions around expanding indicational approval for Acthar based on accumulating clinical evidence, especially in nephrotic syndrome and certain autoimmune diseases. While some applications remain off-label, regulatory agencies are increasingly receptive to data from adaptive trials. In 2022, the FDA granted orphan drug designations for some indications, providing developmental incentives.
Safety and Efficacy Data
Recent clinical evidence emphasizes Acthar's immunomodulatory mechanism, which involves corticosteroid-like activity but with a distinct pharmacodynamics profile. Long-term safety data affirm manageable adverse events, primarily hypertension, infection susceptibility, and metabolic effects. Efficacy data remain consistent in approved indications but are heterogeneous outside these areas.
Market Analysis
Current Market Size
Estimates value the global Acthar market—including branded and biosimilar versions—at approximately $600 million in 2022, driven by its core indications: multiple sclerosis exacerbations, infantile spasms, and other approved inflammatory disorders ([1]). The U.S. accounts for the majority share, owing to high demand, reimbursement trends, and ongoing off-label prescribing.
Key Market Drivers
-
Broad Off-Label Use: Despite limited formal approval, clinicians frequently prescribe Acthar for conditions such as nephrotic syndrome, multiple sclerosis, and autoimmune skin diseases, significantly expanding market potential.
-
New Indication Pursuits: Expansion efforts, including clinical trials in autoimmune and inflammatory diseases, could unlock additional revenue streams if successful and approved.
-
Reimbursement Trends: While historically facing challenges due to high costs and insurance restrictions, recent negotiations and formulary placements have improved access, particularly in chronic neurological and autoimmune conditions.
-
Competitive Landscape: The market faces competition from high-dose corticosteroids, plasma exchange, and newer biologics such as rituximab and eculizumab, especially in refractory or complex cases. Biosimilar entries are still emerging, marginally pressuring pricing.
Market Challenges
-
Pricing and Cost-Effectiveness: Acthar remains one of the most expensive injectables, with list prices exceeding $39,000 per vial for many formulations. Cost-effectiveness debates persist, especially outside FDA-approved labels.
-
Regulatory and Reimbursement Environmental: Increasing scrutiny over off-label use and costs pressures could influence prescribing trends.
-
Patent and Exclusivity Landscape: Several patents related to manufacturing processes and formulations have recently expired or are set to expire, potentially opening the door for biosimilar competition.
Future Market Projections
The overall market CAGR is projected at 3-5% through 2030, contingent on several key factors:
-
Expanded Indications: Successful phase 3 trial outcomes in autoimmune and inflammatory diseases could catalyze a 10-15% uplift in market size.
-
Biosimilar Introductions: Entry of biosimilars could reduce prices and expand access but might erode branded sales.
-
Regulatory Approvals and Label Expansion: Additional approved indications would underpin sustained growth, especially if integrated into treatment algorithms for emerging diseases.
Future Outlook and Strategic Considerations
Innovation and Differentiation
To maintain market relevance, Mallinckrodt and competitors need to focus on demonstrating clinical benefits over existing therapies, managing costs, and leveraging regulatory incentives for novel indications.
Market Expansion Strategies
-
Maximize Off-Label Use with Caution: Encouraging evidence-based expansion into new indications can drive sales but requires careful regulatory navigation.
-
Pricing and Reimbursement Strategy: Engaging payers early to establish value propositions can mitigate access hurdles.
-
Research and Development: Investing in biomarker-driven trials and combination therapies could position Acthar as a pivotal component in complex autoimmune regimens.
Key Takeaways
-
Clinical trials for Acthar continue to explore its use in autoimmune and inflammatory diseases beyond current approved indications, with positive preliminary data supporting further development.
-
Market size is substantial but faces challenges due to high costs, competition, and regulatory scrutiny, especially concerning off-label use.
-
Projected modest growth will depend heavily on successful indication expansion, regulatory approvals, and management of biosimilar competition.
-
Cost-effectiveness and payer engagement remain central to expanding access and maintaining market share.
-
Strategic focus on clinical differentiation, indication expansion, and stakeholder engagement can secure Acthar’s future in a competitive therapeutic landscape.
FAQs
1. What are the primary approved indications for Acthar?
Acthar is FDA-approved for multiple sclerosis exacerbations, infantile spasms, and certain inflammatory and autoimmune conditions, including nephrotic syndrome and vasculitis.
2. Are there ongoing clinical trials investigating new uses for Acthar?
Yes, multiple phase 2 and phase 3 trials are exploring Acthar's efficacy in conditions such as systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune disorders.
3. How does the pricing of Acthar impact its market adoption?
Acthar's high cost—over $39,000 per vial—limits its use to serious cases and insured populations willing to navigate payer restrictions. Cost-effectiveness remains a contentious issue influencing formulary decisions.
4. What is the potential impact of biosimilars on the Acthar market?
Biosimilar development could lower prices and increase access but might also reduce the revenue stream for the branded product, prompting strategic adjustments.
5. What are the regulatory prospects for expanding Acthar’s indications?
Regulatory approvals hinge on positive clinical trial data and demonstrated safety profiles. Successful indication expansion could significantly enhance market size and revenue.
References
[1] Market data and analysis based on industry reports and recent sales figures available as of 2022.
